NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

PSTV

Plus Therapeutics Inc

Jul 09 • 09:35AM ET

0.3422

Dollar change +0.0090
Percentage change 2.70	%

Healthcare • Biotechnology • USA • NASD

Peers: ADAP SUPN KPTI IMUX MEIP PBYI CRIS RIGL SYBX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.50	Insider Own	0.62%	Shs Outstand	51.00M	Perf Week	10.35%
Market Cap	17.45M	Forward P/E	-	EPS next Y	-0.43	Insider Trans	0.00%	Shs Float	50.68M	Perf Month	5.13%
Enterprise Value	7.62M	PEG	-	EPS next Q	-0.09	Inst Own	3.14%	Short Float	2.30%	Perf Quarter	-58.67%
Income	-27.12M	P/S	3.35	EPS this Y	66.32%	Inst Trans	-26.81%	Short Ratio	0.04	Perf Half Y	-72.18%
Sales	5.21M	P/B	-	EPS next Y	35.03%	ROA	-306.82%	Short Interest	1.17M	Perf YTD	-70.24%
Book/sh	-1.39	P/C	1.77	EPS next 5Y	49.58%	ROE	-	52W High	2.31 -85.19%	Perf Year	-77.92%
Cash/sh	0.19	P/FCF	-	EPS past 3/5Y	47.98% 46.51%	ROIC	-	52W Low	0.16 109.42%	Perf 3Y	-95.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -3.61%	Gross Margin	83.73%	Volatility	11.02% 17.67%	Perf 5Y	-98.92%
Dividend TTM	-	EV/Sales	1.46	EPS Y/Y TTM	16.04%	Oper. Margin	-286.82%	ATR (14)	0.06	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	0.99	Sales Y/Y TTM	-14.43%	Profit Margin	-520.90%	RSI (14)	50.94	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	0.99	EPS Q/Q	-58.31%	SMA20	14.78%	Beta	0.64	Target Price	9.12
Payout	-	Debt/Eq	-	Sales Q/Q	-36.85%	SMA50	-15.24%	Rel Volume	3.22	Prev Close	0.33
Employees	21	LT Debt/Eq	-	Earnings	May 30 BMO	SMA200	-65.11%	Avg Volume	26.54M	Price	0.34
IPO	Oct 22, 2003	Option/Short	No / Yes	EPS/Sales Surpr.	-379.65% -28.61%	Trades		Volume	5,308,695	Change	2.70%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-25	Initiated	D. Boral Capital	Buy	$9
Jan-25-21	Initiated	Ladenburg Thalmann	Buy	$8
Oct-16-20	Initiated	Maxim Group	Buy	$6

Jul-08-25 07:30AM	Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases (GlobeNewswire) +10.88%
Jun-30-25 07:30AM	Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases (GlobeNewswire) +10.38%
Jun-26-25 08:26AM	FDA approves Plus Therapeutics' Reyobiq for paediatric brain cancer (Pharmaceutical Business Review) +16.38%
07:30AM	Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary (GlobeNewswire)
Jun-25-25 04:15PM	Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET (GlobeNewswire) +68.45%
07:30AM	Loading…
07:30AM	Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer (GlobeNewswire)
Jun-24-25 07:30AM	Plus Therapeutics Announces Comprehensive Restructuring of $15 Million March 2025 Equity Financing (GlobeNewswire)
Jun-19-25 12:00PM	Plus (PSTV) Upgraded to Buy: Here's Why (Zacks)
May-30-25 05:25PM	Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +28.16%
05:20PM	Nutriband Inc. (NTRB) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights (GlobeNewswire)
May-29-25 05:30PM	The Cooper Companies (COO) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
May-23-25 04:15PM	Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
May-15-25 05:40PM	Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -17.09%
May-14-25 10:00AM	Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) -24.05%
08:15AM	Loading…
08:15AM	Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Plus Therapeutics' REYOBIQ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM) (GlobeNewswire)
May-12-25 05:10PM	Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +8.74%
May-08-25 08:00AM	Aclaris Therapeutics (ACRS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +10.01%
07:00AM	Plus Therapeutics to Participate in the D. Boral Capital Inaugural Global Conference (GlobeNewswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks) -14.32%
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks) +24.97%
08:00AM	Plus Therapeutics Announces Biotech Industry Veteran Kyle Guse Joins its Board of Directors (GlobeNewswire)
Apr-15-25 07:30AM	Plus Therapeutics Presents New Data Highlighting Clinical Benefit and Safety of REYOBIQ in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (GlobeNewswire)
Apr-01-25 12:00PM	Plus (PSTV) Upgraded to Buy: Here's What You Should Know (Zacks) +7.36%
Mar-28-25 01:12PM	Q4 2024 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -23.68%
03:04AM	Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Mar-27-25 07:42PM	Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript (SeekingAlpha)
05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
12:17PM	Loading…
Mar-21-25 12:17PM	PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug (Zacks) -14.49%
06:34AM	Why Plus Therapeutics Inc. (PSTV) Surged On Thursday? (InsiderMonkey)
Mar-20-25 07:30AM	Plus Therapeutics Introduces REYOBIQ , FDA-Accepted Proprietary Name for Lead Drug Candidate (GlobeNewswire) +170.06%
Mar-19-25 07:30AM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 27, 2025 (GlobeNewswire) -8.44%
Mar-11-25 11:00AM	D. Boral Capital Served as Exclusive Placement Agent to Plus Therapeutics, Inc. (Nasdaq:PSTV) in Connection with its up to $15.0 Million Private Placement (ACCESSWIRE) +12.60%
Mar-10-25 07:30AM	Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement (GlobeNewswire) -19.11%
Mar-07-25 01:49PM	Why Plus Therapeutics, Inc. (PSTV) Soared on Thursday (Insider Monkey) +9.03%
07:33AM	FDA ODD given to Plus Therapeutics injectable radiotherapy (Pharmaceutical Technology)
07:30AM	Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma (GlobeNewswire)
Mar-06-25 07:30AM	Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer (GlobeNewswire) +311.43%
Mar-05-25 04:01PM	Plus Therapeutics Announces New Employment Inducement Grants (GlobeNewswire) +15.82%
Mar-04-25 02:06PM	Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds (GlobeNewswire) -54.21%
Feb-26-25 07:30AM	Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases (GlobeNewswire) -29.63%
Feb-24-25 07:30AM	Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary (GlobeNewswire) -5.00%
Feb-20-25 07:30AM	Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer (GlobeNewswire)
Feb-18-25 07:30AM	Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program (GlobeNewswire)
Dec-17-24 07:30AM	Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Breast Cancer Patients with Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire) -8.55%
Dec-04-24 07:30AM	Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-03-24 07:30AM	Plus Therapeutics Expands Strategic Agreement with Telix IsoTherapeutics Group for Rhenium-186 Radioisotope Supply (GlobeNewswire)
Nov-25-24 09:48AM	CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis (Medical Device Network)
07:30AM	Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 Interim Data for Leptomeningeal Metastases at the 2024 SNO Annual Conference (GlobeNewswire)
Nov-22-24 07:30AM	Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases (GlobeNewswire)
Nov-21-24 07:30AM	Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases (GlobeNewswire)
Nov-15-24 02:16AM	Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) -7.14%
Nov-14-24 04:15PM	Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-07-24 07:18AM	Plus Therapeutics partners with SpectronRx for CNS therapy development (Pharmaceutical Business Review)
Nov-06-24 07:30AM	Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership (GlobeNewswire) +5.15%
Nov-05-24 07:30AM	Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 (GlobeNewswire)
Oct-29-24 07:30AM	Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas (GlobeNewswire)
Oct-01-24 07:30AM	Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting (GlobeNewswire) -10.27%
Sep-18-24 07:30AM	Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting (GlobeNewswire)
Sep-04-24 07:30AM	Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire)
Aug-15-24 09:42AM	Q2 2024 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-14-24 09:53PM	PSTV Stock Earnings: Plus Therapeutics Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
04:16PM	Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-13-24 07:30AM	Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference (GlobeNewswire) +5.67%
Aug-12-24 07:30AM	Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference (GlobeNewswire)
Aug-08-24 07:30AM	Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Plus Therapeutics Showcases Leptomeningeal Metastases Programs at 2024 SNO/ASCO Conference (GlobeNewswire)
Jul-02-24 07:30AM	Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer (GlobeNewswire)
Jun-07-24 07:30AM	Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT (GlobeNewswire) -5.24%
May-17-24 05:00PM	Plus Therapeutics Announces New Employment Inducement Grants (GlobeNewswire)
May-16-24 03:05AM	Plus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ... (GuruFocus.com)
May-15-24 08:53PM	PSTV Stock Earnings: Plus Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +6.91%
04:15PM	Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
May-13-24 07:30AM	Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024 (GlobeNewswire)
May-09-24 11:29AM	Plus Therapeutics Provides Highlights Regarding Leptomeningeal Metastases Acquisition and Topline Clinical Trial Data on the FORESEE Trial (GlobeNewswire)
May-08-24 05:35PM	Plus Therapeutics to Host Investor Call to Discuss Leptomeningeal Cancer Related Acquisition and Topline Clinical Trial Data from the FORESEE Trial (GlobeNewswire) +6.57%
May-06-24 07:30AM	Plus Therapeutics Announces Private Placement Financing of up to $18 Million (GlobeNewswire) +11.67%
Apr-22-24 09:00AM	Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense (Benzinga)
07:00AM	Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense (GlobeNewswire)
Apr-09-24 07:00AM	Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team (GlobeNewswire)
Mar-27-24 08:00AM	Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference (GlobeNewswire)
Mar-25-24 08:00AM	Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic (GlobeNewswire)
Mar-11-24 07:00AM	Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases (GlobeNewswire)
Mar-07-24 08:59AM	Plus Therapeutics, Inc. (NASDAQ:PSTV) Q4 2023 Earnings Call Transcript (Insider Monkey) -10.59%
Mar-06-24 01:43PM	Q4 2023 Plus Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -11.24%
Mar-05-24 09:52PM	PSTV Stock Earnings: Plus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
05:35PM	Plus Therapeutics (PSTV) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights (GlobeNewswire)
Feb-27-24 08:00AM	Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024 (GlobeNewswire) +6.01%
Dec-18-23 07:00AM	Plus Updates Financial and Cash Guidance for 2024 (GlobeNewswire)
Dec-12-23 08:00AM	Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses (GlobeNewswire)
Nov-29-23 08:00AM	Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe (GlobeNewswire) -5.56%
Nov-20-23 07:00AM	Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar (GlobeNewswire) -27.76%
Nov-15-23 07:00AM	Plus Therapeutics to Host Virtual KOL Event on New Phase 2 ReSPECT-GBM Data in Recurrent Glioblastoma Presented at the Society for NeuroOncology (SNO) Conference on Monday, November 20, 2023 (GlobeNewswire) +12.43%
Nov-13-23 09:31AM	Thinking about buying stock in Tivic Health Systems, Tigo Energy, TAT Technologies, Plus Therapeutics, or Acumen Pharmaceuticals? (PR Newswire)
Nov-03-23 07:00AM	Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to Rhenium (186Re) Obisbemeda for the Treatment of Breast Cancer with Leptomeningeal Metastases (GlobeNewswire) +17.65%
Nov-01-23 09:29AM	Plus Therapeutics, Inc. (NASDAQ:PSTV) Q3 2023 Earnings Call Transcript (Insider Monkey) +5.74%
Oct-31-23 04:10PM	Plus Therapeutics Announces Share Repurchase Program (GlobeNewswire) +10.92%

Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company. The firm focuses on the development of chemotherapeutics and radio therapeutics for rare cancers that address unmet medical and market needs. Its products include Rhenium NanoLiposome and DocePLUS. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in Houston, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Petersen Greg	Director	May 15 '25	Proposed Sale	0.55	36,666	20,276		May 07 11:59 AM
Hawkins Richard J	Director	Sep 13 '24	Buy	1.50	4,000	5,996	15,188	Sep 17 07:00 AM
Hawkins Richard J	Director	Sep 12 '24	Buy	1.35	6,285	8,512	11,188	Sep 16 07:00 AM
Petersen Greg	Director	Sep 11 '24	Buy	1.35	12,500	16,875	48,921	Sep 13 06:04 AM
Clowes Howard	Director	Sep 11 '24	Buy	1.34	5,000	6,681	26,497	Sep 13 06:04 AM
HEDRICK MARC H	Chief Executive Officer	Sep 10 '24	Buy	1.23	8,000	9,839	20,425	Sep 11 06:02 AM
Sims Andrew John Hugh MacIntyr	Chief Financial Officer	Sep 10 '24	Buy	1.27	4,098	5,204	9,815	Sep 11 06:02 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PSTV

Plus Therapeutics Inc

Upgrade your FINVIZ experience